Skip to main content

Table 2 Comparison of baseline characteristics between the PET negative and PET positive groups

From: Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with small hepatocellular carcinoma treated by radiofrequency ablation

  PET negative (n = 110) PET positive (n = 11) p value
Age (years) 69 (45–87) 76 (58–83) 0.401
Sex (male/female) 68/42 5/6 0.341
Etiology (HCV/non-HCV) 82/28 9/2 0.730
Fibrosis stage (F0–3/4) 39/71 5/6 0.526
Child–Pugh class (A/B) 87/23 10/1 0.691
Platelets (× 104/μL) 9.0 (2.4–75.9) 10.4 (2.9–21.2) 0.351
ALT (IU/L) 37 (10–171) 45 (16–133) 0.339
Hyaluronic acid (ng/mL) 216.3 (23.2–1851.9) 265.5 (85.0–884.9) 0.438
Type IV collagen 7S (ng/mL) 7.7 (3.0–18.0) 7.3 (4.1–12.9) 0.487
Tumor size (mm) 18 (8–30) 25 (15–30) 0.001
Number of tumors (1/2/3) 91/14/5 8/2/1 0.413
AFP (ng/mL) 16.1 (1.8–1594.5) 112.1 (3.1–1545.8) 0.011
AFP-L3 (%) 7.3 (0–72.5) 28.9 (0–80.0) 0.011
DCP (mAU/mL) 58 (5–9489) 177 (22–2615) 0.008
  1. HCV hepatitis C virus, ALT alanine aminotransferase, HCC hepatocellular carcinoma, AFP alpha-fetoprotein, AFP-L3 Lens culinaris agglutinin-reactive alpha-fetoprotein, DCP Des-gamma-carboxyprothrombin, PET positron emission tomography. Data are expressed as medians (range)